CSL (ASX:CSL): Is This Healthcare Giant Still a Staple in ASX200?

May 02, 2025 12:55 PM AEST | By Team Kalkine Media

Google News:

CSL (ASX:CSL): Is This Healthcare Giant Still a Staple in ASX200? — Image source: shutterstock

Recent News

Bravery Over Bladder: Former Marine Tackles Taboo Topic

Forward Air stock surges on report PE firms express acquisition intere...

RBC initiates Knife River, Martin Marietta amid continued infrastructu...

WP Engine Celebrates 15 Years of Innovation

Highlights

CSL revenue grows at 12.8% CAGR over three years

Profit reaches $2.64 billion in FY24

Debt/equity ratio remains balanced at 62.8%

Shares of biotechnology heavyweight CSL (ASX:CSL) have seen a decline of 10.69% since the start of 2025, sparking renewed interest from investors looking into quality ASX200 healthcare stocks. Despite recent price movements, the underlying fundamentals of the company remain notable and are worth a closer look.

CSL operates through three main divisions: CSL Behring, CSL Seqirus, and CSL Vifor. Behring focuses on blood plasma therapies, Seqirus manufactures flu vaccines and engages in pandemic-related services, while Vifor provides treatments for iron deficiency and renal conditions. This diversified model gives CSL a strong footing across essential healthcare areas.

Revenue has consistently grown at an impressive pace. CSL reported $14.8 billion in revenue for the last financial year, with a three-year compound annual growth rate (CAGR) of 12.8%. This level of sustained growth underpins its long-standing appeal as a dependable player among ASX dividend stocks.

Profitability metrics also paint a robust picture. The company reported a gross margin of 52.1%, reflecting strong performance from its core products and services. Its net profit climbed to $2.64 billion in FY24, up from $2.38 billion three years ago—an increase at a CAGR of 3.6%.

When it comes to financial strength, CSL maintains a balanced position. The net debt currently stands at $10.5 billion, and its debt-to-equity ratio is 62.8%. While this reflects a moderate level of leverage, it also indicates prudent capital management. Importantly, the return on equity (ROE) of 14.6% suggests that CSL is deploying its shareholders' capital efficiently to generate meaningful returns.

As a recognised leader in the biotechnology space, CSL continues to appeal to investors looking for stable, long-term growth potential within the ASX200. Its inclusion among ASX dividend stocks is also supported by its consistent dividend track record and strong financial fundamentals.

Given the company’s historical performance, diversified business segments, and resilient financial profile, CSL (CSL) remains a significant name in Australia’s healthcare and biotechnology landscape.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.